Nuclear Services Provider Holtec Files for U.S. IPO, Plans Nasdaq Listing
Miles Bennett
Holtec Nuclear, a leading nuclear-waste and decommissioning firm, filed for a Nasdaq IPO on July 10; the company is betting on small modular reactors, yet Q1 revenue and profit both fell year-on-year as valuation doubts over nuclear newcomers widen.
What does this company actually do?
Holtec was founded in 1986 and is based in Camden, New Jersey. Its two core businesses: manufacturing nuclear-waste storage canisters and dismantling retired nuclear plants.
In plain terms = after a nuclear plant shuts down, someone has to package the radioactive waste and tear down the old facility — that is Holtec's business.
The company led the decommissioning of New York's Indian Point nuclear plant and is a major player in U.S. nuclear retirement work.
Equity is held through two trusts controlled by founder and CEO Krishna Singh — a classic founder-dominated ownership structure.
How do the IPO fundamentals look?
JPMorgan, Goldman Sachs, Citi, Bank of America, and Guggenheim Securities are joint underwriters — a top-tier lineup. Ticker: "HNUC."
But the financials are soft: Q1 revenue came in at $165.3 million, down year-on-year; net income was $17.8 million, roughly a 30% drop from $25.4 million a year earlier.
This means → Holtec is listing during a revenue-and-profit dip, which signals the company prioritises opening a capital-markets funding channel now over waiting for a stronger earnings quarter.
Small modular reactors — what is the growth story?
SMRs — small modular reactors, a type of nuclear reactor that is smaller and faster to build than conventional plants — are Holtec's core growth narrative.
In 2022 the company acquired the Palisades nuclear plant in Michigan, originally slated for demolition. Surging data-centre demand for carbon-free power has pushed Palisades close to a restart.
Holtec also plans to install its first self-developed SMR at the Palisades site, targeting commercial operation in the early 2030s.
The U.S. Department of Energy awarded the project a $400 million grant last December — this reflects a real-money federal bet on the SMR pathway.
What does the track record of nuclear newcomers tell us?
Fellow SMR-track firm X-Energy listed in April this year. Its stock rose on day one but has since fallen 31% below its IPO price.
This means → the market is visibly split on when SMRs will actually generate revenue. Day-one hype does not equal lasting valuation support.
In plain terms = no SMR has reached commercial operation in the U.S. yet; investors are buying a story that won't pay off for at least five years.
Whether Holtec can hold its post-IPO valuation hinges on two things: progress on the Palisades restart and tangible advances in its SMR project.
Content is for reference only, not financial advice.